Compare Amgen, Inc. (AMGN) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Marsh & McLennan Companies, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Marsh & McLennan Companies, Inc. trades at $178.31 (market cap $85.91B). The key difference: Amgen, Inc. is far larger — about 2.3× Marsh & McLennan Companies, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MRSH | |
|---|---|---|
Market Cap | $196.12B | $85.91B |
Sector | Health | Financials |
52-Week High | $388.16 | $213.57 |
52-Week Low | $271.18 | $157.32 |
Enterprise Value | $241.41B | $106.75B |
Dividend Yield | 2.77% | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Marsh (MRSH) trades at $178.31, down 0.39% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.29 exceeding expectations, and recently raised its quarterly dividend by 10% to $0.99 per share. Revenue growth has been steady, reaching $26.98 billion in 2025, supported by a robust net income margin of 14.26%.
The outlook remains positive given consistent earnings outperformance and shareholder returns, though valuation multiples like a P/E of 22.29 and P/B of 5.9 suggest a premium. Risks include easing pricing tailwinds in insurance and rising costs. Analysts are predominantly neutral with a consensus price target of $199.44, indicating modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
